The study of cytokeratin 18 fragments and inflammation related factors in non-alcoholic fatty liver disease
-
摘要: 目的探讨非酒精性脂肪性肝病(NAFLD)伴代谢综合征(MS)的患者细胞角蛋白18片段、炎症相关因子的表达水平,为临床早期预防NAFLD伴有MS的患者向严重肝病进展提供依据。方法采用横断面调查研究,成组设计。入组85例脂肪肝患者及20例正常对照者。根据是否伴MS分为三组:NAFLD+MS组、NAFLD组、NC组。采用酶联免疫吸附法(ELISA)检测各组血清中细胞角蛋白18片段、炎症相关因子肿瘤坏死因子(TNF)α、白细胞介素6(IL-6)表达水平。通过速率散射比浊法检测血清超敏C-反应蛋白(hs-CRP)表达水平。结果 (1)血清细胞角蛋白18片段(M30)在NAFLD+MS组中高表达[(143±38.7)ng/L],与NAFLD组[(125±36.05)ng/L]、NC组[(118±30.40)ng/L]比较差异有统计学意义(P<0.05)。(2)炎症相关因子TNFα在NAFLD+MS组[(316±74.5)ng/L]和NAFLD组[(308.6±87.5)ng/L]升高、与NC组[(241.7±75.8)ng/L]比较差异有统计学意义(P<0.05),在NAFLD组与NA...Abstract: Objective To explore the clinical significance of the blood cytokeratin-18 (CK-18) fragments and inflammation related cytokines level in nonalcoholic fatty liver disease (NAFLD) with metabolism syndrome (MS) , and provide the evidence for preventing severe liver disease in these patients from early stage. Methods A total of 85 cases of NAFLD patient were enrolled in the study and 20 normal were recruited as normal control.All the 85 patients were divided into two groups according to whether or not combined with the metabolic syndrome as (NAFLD +MS) group and NAFLD group and 20 normal cases designated as normal control groups (NC) .Serum level of CK-18 fragment (M30-antigen) and total CK-18 (M65-antigen) and inflammation related cytokines (TNFα、IL-6) were determined by ELISA.Level of hs-CRP was tested by rate of scattering method. Results There was a statistical significance of CK-18 fragment serum level in MS+NAFLD group[ (143±38.7) ng/L] compared to NAFLD group and NC group (F=4.251 and P<0.05 respectively) .Serum TNF-alpha level in MS+NAFLD and NALFD group were higher[ (316±74.5) ng/L] than NC group (F=6.994, P<0.05) .Hs-CRP, IL-6 plasma, ALT and GGT level was higher in MS+NAFLD than in NALFD and NC group (P<0.05) .Conclusion CK-18 fragment combing with inflammation related factors may play a role in monitoring and preventing before severe liver disease in NAFLD.
-
Key words:
- fatty liver /
- metabolic syndrome X /
- cytokines /
- cytokeratin-18 fragment
-
[1]Schwimmer JB, Deutsch R, Kahen T, et al.Prevalence offatty liver in children and adolescents[J].Pediatrics, 2006, 118 (4) :1388-1393. [2]Fan JG, Zhu J, Li XJ, et al.Prevalence of risk factors for fat-ty liver in a general population of Shanghai[J].China J Hep-atol, 2005, 43 (3) :508-514. [3]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志, 2006, 14 (3) :161-163. [4] 中华医学会糖尿病分会.2007年中国2型糖尿病防治指南[J].中华内分泌代谢杂志, 2008, 24 (2) :增录1-附录26. [5]Hashizume H, Sato K, Takagi H, et al.Primary liver cancerwith nonalcoholic steatohepatitis[J].Eur J GastroenterolHepatol, 2007, 19 (10) :827-834. [6]Petta S, CraxìA.Hepatocellular carcinoma and non-alcohol-ic fatty liver disease:from a clinical to a molecular association[J].Curr Pharm Des, 2010, 16 (6) :741-52. [7]钟黄, 李良平.非酒精性脂肪肝、隐源性肝硬化与原发性肝癌发生的关系[J].国际消化病杂志, 2009, 29 (6) :402-405. [8]Alkhouri N, Tamimi TA, Yerian L, et al.The inflamed liverand atherosclerosis:a link between histologic severity ofnonalcoholic fatty liver disease and increased cardiovascularrisk[J].Dig Dis Sci, 2010, 55 (9) :2644-2650. [9]Adams LA, Waters OR, Knuiman MW, et al.NAFLD as arisk factor for the development of diabetes and the metabolicsyndrome:an eleven-year follow-up study[J].Am JGastroenterol, 2009, 104 (4) :861-867. [10]Adams LA, Harmsen S, St Sauver JL, et al.Nonalcoholicfatty liver disease increases risk of death among patientswith diabetes:a community-based cohort study[J].Am JGastroenterol, 2010, 105 (7) :1567-1573. [11]Lizardi-Cervera J, Aguilar-Zapata D.Nonalcoholic fatty liv-er disease and its association with cardiovascular disease[J].Ann Hepatol, 2009, 8 (Suppl 1) :S40-S43. [12]Bantel H, Lugering A, Heidemann J, et al.Detection of ap-optotic caspase activation in sera from patients with chronicHCV infection is associated with fibrotic liver injury[J].Hep-atology, 2004, 40 (5) :1078-1087. [13]Wieckowska A, Zein NN, Yerian LM, et al.In vivo assess-ment of liver cell apoptosis as a novel biomarker of diseaseseverity in nonalcoholic fatty liver disease[J].Hepatology, 2006, 44 (1) :27-31. [14]Feldstein AE, Wieckowska A, Lopez AR, et al.Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalco-holic steatohepatitis:a multicenter validation study[J].Hepatology, 2009, 50 (4) :1072-1078. [15]Canbakan B, Senturk H, Canbakan M, et al.Is alanine amin-otransferase level a surrogate biomarker of hepatic apoptosisin nonalcoholic fatty liver disease?[J].Biomark Med, 2010, 4 (2) :205-214. [16]Iubitskaia NS, Antoniuk MV, Veremchuk LV, et al.Role oftumor necrosis factor in the development of metabolic syn-drome[J].Ter Arkh, 2009, 81 (11) :59-63. [17]Riquelme A, Arrese M, Soza A, et al.Non-alcoholic fattyliver disease and its association with obesity, insulin resist-ance and increased serum levels of C-reactive protein inHispanics[J].Liver Int, 2009, 29 (1) :82-88. [18]Lemoine M, Ratziu V, Kim M, et al.Serum adipokine levelspredictive of liver injury in non-alcoholic fatty liver disease[J].Liver Int, 2009, 29 (9) :1431-1438. [19]Manco M, Marcellini M, DeVito R, et al.Metabolic syndromeand liver histology in paediatric non-alcoholic steatohepatitis[J].International Journal of obesity, 2008, 32 (2) :381-387. [20]Valva P, De Matteo E, Galoppo MC, et al.Apoptosis mark-ers related to pathogenesis of pediatric chronic hepatitis C vi-rus infection:M30 mirrors the severity of steatosis[J].JMed Virol, 2010, 82 (6) :949-957.
本文二维码
计量
- 文章访问数: 249
- HTML全文浏览量: 15
- PDF下载量: 147
- 被引次数: 0